Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA
Post by: Colleen Parr Dekker
November 14, 2016, Greenfield, Indiana – Elanco’s novel in-feed treatment has been approved for the prevention and control of sea lice in salmon and trout in Chile. Sea lice are a significant challenge for salmon farmers, and this new breakthrough tool offers an innovative, long-acting treatment alternative. Chile is the first country to grant marketing authorization to the treatment.
The approval in Chile follows the completion of a series of studies, demonstrating its efficacy against Caligus rogercresseyi1, the most common louse species impacting salmonid farms in Chile. The study demonstrated that salmon treated with the medication remained below the Chilean industry regulated threshold for an extended period of time, compared to the untreated group, which exceeded the threshold five times in the same period.2
“After years of dedicated research working with farmers and industry experts, Elanco is proud to bring this much-needed treatment to salmon farms in Chile, and is working hard to bring it to other markets around the world,” said Carlos Kuada, Global Head of Aqua Business, Elanco Animal Health. “Managing these parasites is a constant strain on salmon farmers – it is time consuming, cumbersome, and stressful to both fish and farmers. This option can help provide relief from sea lice management for an extended period of time, alleviating that stress.”
The treatment is given in feed to fish in fresh water before they are transferred to the sea. Studies have shown that it inhibits the formation of chitin in sea lice, which prevents the lice from developing into adults.
Fish treated with the medication are already accepted for trade with major export markets, including the US, EU, Norway, Chile, Japan and Brazil.
Sea lice are estimated to cost the global industry more than $1 billion per year.3 Current treatments are often highly disruptive to salmon farms, as many require sea bath treatments. Additionally, the efficacy of some treatments is limited due to the emergence of drug resistance. To date, no resistance in sea lice has been detected in this novel treatment.
Elanco is currently working with authorities in other countries to help bring this potentially important solution to market as soon as possible.
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. With a global presence of approximately 6,500 people and offices in more than 40 countries, Elanco anticipates, serves and supports the diverse and evolving needs of its customers – from veterinarians to food producers to all those concerned with animal health – to help them address the challenges of a diverse and changing world, and to advance a vision of food and companionship enriching life. Elanco is committed to raising awareness about global food security, and to celebrating and supporting the human-animal bond. Elanco is a division of Eli Lilly and Company, a Fortune 500 global pharmaceutical corporation in Indianapolis with a heritage more than 140 years strong.
Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.